Genital herpes cannot be cured. Once you’re infected with herpes simplex virus type 2 (HSV-2), it stays in your body for life. No medication, supplement, or treatment available today can fully eliminate the virus. But that headline doesn’t tell the whole story. While you can’t get rid of genital herpes, you can reduce outbreaks to near zero, cut transmission risk dramatically, and live with minimal impact on your daily life. Roughly 520 million people worldwide between ages 15 and 49 carry HSV-2, so if you’re dealing with this, you’re far from alone.
Why the Virus Can’t Be Cleared
HSV-2 is permanently embedded in your nervous system because of how it hides. After the initial infection, the virus travels along nerve fibers and settles into clusters of nerve cells near the base of your spine called the sacral ganglia. There, it enters a dormant state called latency, where it essentially goes silent. It stops replicating and produces almost no viral proteins that your immune system could detect and target.
The key to this hiding act is a set of molecules called latency-associated transcripts, or LATs. These are the only thing the virus actively produces while dormant. LATs appear to protect the infected nerve cell from self-destructing (a normal defense mechanism cells use against viruses) and may also suppress the genes the virus would need to reactivate. Because the virus isn’t replicating during latency, antiviral drugs that work by blocking viral replication have no effect on it while it’s hiding. Your immune system, meanwhile, can’t see it. It’s like a burglar sitting silently in a locked room with no windows.
Periodically, the virus reactivates, travels back down the nerve fibers to the skin, and either causes visible sores or sheds invisibly at the surface. This is when outbreaks happen, and also when transmission to partners is possible, even without symptoms.
What Antiviral Treatment Actually Does
Antiviral medications don’t cure herpes, but they meaningfully change the experience of living with it. The most commonly prescribed options work by blocking the virus from copying itself during reactivation. You can take them two ways: episodic therapy (taking them when you feel an outbreak starting) or daily suppressive therapy (taking them every day to prevent outbreaks from happening in the first place).
Daily suppressive therapy does more than just reduce your own symptoms. A landmark trial published in the New England Journal of Medicine found that daily use of valacyclovir reduced the risk of transmitting HSV-2 to an uninfected partner by about 48% overall. Clinically symptomatic infections in partners dropped by 75%. Combined with condom use, the reduction is even greater. For many couples where one partner has herpes and the other doesn’t, daily suppressive therapy is the cornerstone of a prevention strategy.
Most people on daily suppressive therapy experience few or no outbreaks. Over time, even without medication, outbreaks tend to become less frequent and less severe as the immune system builds a stronger response to the virus.
How Much Condoms Help
Condoms provide real but imperfect protection against HSV-2 because the virus can shed from skin that a condom doesn’t cover. That said, the protection is more significant than many people realize, and it varies by direction of transmission. Research from the University of Witwatersrand found that male condom use reduced the per-act risk of HSV-2 transmission from men to women by 96%, and from women to men by 65%. The difference likely reflects how much infectious skin contact occurs outside the area a condom covers in each scenario.
When combined with daily antiviral therapy and avoiding sex during active outbreaks, condoms bring the overall risk of passing herpes to a partner down substantially.
A New Class of Drug on the Horizon
A medication called pritelivir works through a completely different mechanism than traditional antivirals. Instead of requiring activation by a viral enzyme (the way acyclovir-based drugs work), pritelivir directly blocks a protein complex the virus needs to copy its DNA. This makes it more effective at healing lesions and reducing viral shedding, and it can even prevent the virus from entering uninfected cells.
The FDA has granted pritelivir a breakthrough therapy designation, which fast-tracks review for drugs that treat serious conditions. The company developing it, Aicuris, has indicated plans to file for FDA approval. If approved, pritelivir would be the first new class of anti-herpes drug in decades, particularly important for people whose virus has developed resistance to existing treatments.
Gene Editing: The Closest Thing to a Cure
The most promising avenue for actually eliminating HSV from the body is gene editing. Researchers at Fred Hutchinson Cancer Center have developed an approach using engineered proteins called meganucleases, delivered into nerve cells by harmless viral carriers. These meganucleases are designed to find the herpes DNA hiding inside nerve cells and cut it apart.
In mouse models, this approach has eliminated over 90% of latent HSV-1 DNA from nerve clusters, and up to 97% in models of genital infection. That’s a staggering reduction, though moving from mice to humans involves significant challenges, including safely delivering the gene-editing tools to the right nerve cells deep inside a living person. This research was published in Nature Communications in 2024, and clinical trials in humans have not yet begun.
Vaccines in Development
There is no vaccine available for genital herpes, either to prevent infection or to reduce symptoms in people who already have it. Several candidates have been tested in recent years with mixed results.
GSK tested a therapeutic vaccine (designed to reduce outbreaks in people already infected) through a phase I/II trial. The vaccine did not meet its primary efficacy endpoint, and GSK has confirmed it will not move to phase III studies. Moderna is further along with mRNA-1608, an mRNA-based therapeutic vaccine currently in a phase 1/2 trial with about 300 participants. Interim results have been reported through six months after the second dose, though full efficacy data are still pending.
Living With HSV-2 in Practical Terms
For most people, genital herpes becomes a manageable condition rather than a defining one. First outbreaks tend to be the worst, with subsequent episodes becoming shorter and milder. Many people with HSV-2 have infrequent outbreaks or none at all after the first year or two. The virus does shed asymptomatically, meaning it can be present on the skin surface without causing visible sores, which is why transmission can happen even between outbreaks.
The combination of daily suppressive therapy, condom use, and avoiding sexual contact during active outbreaks reduces transmission risk to a level many couples find acceptable. Disclosure to partners remains important because it allows both people to make informed decisions about protection.
Pregnancy and Herpes
One area where genital herpes carries serious medical stakes is childbirth. A baby exposed to HSV during vaginal delivery can develop neonatal herpes, a rare but dangerous condition. The risk depends heavily on timing. If a mother acquires a brand-new herpes infection near the time of delivery, transmission rates to the newborn can reach up to 60%. But for mothers with a recurrent infection (meaning they’ve had herpes for a while and their body has built antibodies), the transmission risk drops to less than 2%. Those maternal antibodies cross the placenta and help protect the baby.
Cesarean delivery reduces the risk further when active lesions are present at the time of labor. Most women with a history of genital herpes are prescribed suppressive antiviral therapy starting around 36 weeks of pregnancy to reduce the chance of an active outbreak at delivery.